The enzyme myeloperoxidase (MPO) is synthesized only in myeloid and monocytic cells, making it an important marker of the myeloid lineage. Transcription of the MPO gene is turned on early during the myeloblast stage of myeloid differentiation and is turned off when myeloid precursors are induced to differentiate along any one of a number of pathways. MPO transcripts show heterogeneity in size and sequence due, in part, to differential RNA splicing. We recently reported transfection studies which showed the presence of three distinct MPO promoters in the 5Ј-flanking region of the human MPO gene, suggesting that MPO transcription may also be regulated through the use of multiple promoters. We now report results of primer extension and RT-PCR experiments designed to determine if transcription of the human MPO gene is initiated at multiple promoter sites in vivo. MPO RNA obtained from myeloid cell lines was analyzed by primer extension using primers located at various sites between bp −1100 and bp +120 of the MPO gene. In addition, RT-PCR experiments were carried out using primer pairs located at intervals between bp −1000 and bp +2500 of the MPO gene. MPO transcripts were found to be initiated at three sites located about bp −920, bp −310, and bp +1 of the MPO gene, corresponding closely to our previously described P3, P2 and P1 promoters, respectively. Transcription initiated at the P1 site gave rise to large transcripts and showed the expected downregulation following induction of differentiation. On the other hand, transcripts initiated at the P3 and P2 sites did not show downregulation following induction of macrophage differentiation by TPA, and most did not appear to extend into the MPO coding region. Northern blot analysis of transcripts initiated at the P3 and P2 sites suggested that transcription at these sites was non-tissue-specific and indicated that many of these transcripts undergo premature termination. These results demonstrate that the MPO gene is transcribed in vivo primarily using the P1 promoter and that the low level of transcription occurring at the P2 and P3 sites is nonspecific and does not contribute significantly to physiologic regulation of MPO gene expression.
Introduction
Myeloperoxidase (MPO), an important enzyme involved in the defense against bacterial and fungal infection, is present in large quantities in the primary granules of developing neutrophils 1 . More importantly from a clinical standpoint, MPO enzyme activity is found exclusively in granulocytes and monocytes, making it an important marker of myeloid differentiation, which is used in the classification of acute leukemias tially the same tissue specificity as that of MPO enzyme activity. 3 MPO RNA synthesis in developing myeloid cells begins during the myeloblast stage of differentiation and continues until the end of the promyelocyte stage, at which point transcription of this gene rapidly ceases 4, 5 . Early sequencing studies of murine MPO clones by Venturelli et al 6, 7 suggested that several start sites are used for MPO transcription in mouse myeloid cells, raising the possibility that regulation of MPO transcription in this species might involve the use of multiple distinct MPO promoters. Friedman and co-workers 8 mapped the initiation site for MPO transcription in the murine cell line 32D Cl3, by Northern blotting and primer extension experiments. Their findings suggested that at least three and possibly four initiation sites for MPO transcription are used in 32D Cl3 cells. To further evaluate the possible use of multiple MPO promoters in murine myeloid cells, we carried out transient transfection experiments designed to look for multiple promoters near the sites suggested by the data of Friedman et al. Our results 9 demonstrated the existence of four distinct murine MPO promoters, which corresponded in location with the initiation sites previously demonstrated by sequence analysis of murine MPO cDNA clones.
Analysis of human MPO mRNA populations and cDNA clones synthesized by reverse transcription of total MPO mRNA extracted from the myeloblast cell line, HL-60, by us and by other investigators [10] [11] [12] [13] [14] and from the monocytic leukemia cell line, SKM-1, by Hosokawa et al 15 revealed several different size classes of MPO mRNA which appeared to arise by differential processing of the primary MPO transcript. However, none of these studies revealed more than a single initiation site for transcription of the human MPO gene, although unpublished evidence cited by Johnson and Nauseef 16 and Friedman et al 8 suggested the possibility of minor usage of one or more upstream MPO initiation sites in HL-60 cells.
Several years ago we isolated and characterized a single human MPO promoter (which we termed 'P1') which was located between bp −128 and bp +11 of the MPO gene. 17, 18 The location of this promoter corresponded closely with the MPO transcription initiation site described by Morishita et al 19 on the basis of S1 mapping experiments, and confirmed by Hashinaka et al 12 and Chang et al. 14 However, more recently, we reported the existence of two additional human MPO promoters (termed 'P2' and 'P3'), whose activity could be demonstrated in transient transfection experiments. 9 Although we did not accurately localize the upstream promoters in these transfection studies, the P2 and P3 promoters appeared to be located approximately 500 bp and 1000 bp upstream from the P1 promoter, respectively. None of these three basal promoters, in themselves, showed tissue specificity or maturation stage specificity in transfection experiments, although addition of various enhancer elements conferred degrees of specificity upon the various promoters. More recently still, Chumakov et Leukemia al 20 reported finding endogenous MPO promoter activity only when they used a 1 kb segment of the MPO gene, extending from about bp −1000 to bp +1, suggesting the possibility that an MPO promoter existed near bp −1000 in the MPO promoter region. In summary, the bulk of previously available evidence suggested that the P1 promoter site is likely to be responsible for initiation of most intact MPO transcripts synthesized in untreated HL-60 cells. However, it remained possible that other initiation sites could be used at different stages of myeloid differentiation or in different hematopoeitic cells or cell lines.
To evaluate the relative contribution of the three human MPO promoters (P1, P2 and P3) identified in transfection experiments, to physiologic tissue-specific and maturationspecific transcription of the MPO gene in immature myeloid cells, we have now carried out a series of primer extension and RT-PCR experiments designed to detect and analyze the 5Ј-ends of MPO transcripts present in whole cell RNA isolated from leukemic cell lines which are known to express (HL-60) or not to express (K-562) intact MPO mRNA and protein, and from a carcinoma line which does not express MPO. Our results yield the surprising result that MPO transcripts are initiated in both myeloid and non-myeloid cells. However, tissue specific-and maturation stage-specific transcription of the MPO gene appears to be carried out primarily by the P1 promoter. The more upstream promoters (P2 and P3) appear to initiate transcription of the MPO gene in both myeloid and non-myeloid cells, but many, and probably most, of these transcripts undergo premature termination and hence do not code for intact MPO protein.
Experimental procedures

Propagation of cells and preparation of RNA
The human cell lines HL-60 (myeloblastic), K-562 (erythroleukemic), and HeLa (squamous carcinoma) were obtained from the American Type Culture Collection (Rockville, MD, USA). All of these cell lines were grown in humidified 5% CO 2 at 37°C in RPMI 1640 (Gibco BRL, Gaithersburg, MD, USA) supplemented with 1% L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% heat-inactivated fetal calf serum. HL-60 cells and K-562 cells were induced to differentiate by growth for 48 h in 10 ng/ml 12-Otetradecanoylphorbol 13-acetate (TPA). In some experiments HeLa cells were subjected to the same treatment. Cells were harvested by centrifugation and washed in phosphate-buffered saline (pH 7.4) before processing. Total cellular RNA was isolated using TRI Reagent (Molecular Research Center, Cincinnati, OH, USA).
Preparation of oligonucleotides
Oligonucleotides (20 to 35 bp in length) for RT-PCR or primer extension experiments were synthesized using a Model 394 DNA/RNA Synthesizer (Applied Biosystems, Foster City, CA, USA). Selection of primers was done using the computer program Oligo (National Bioscience, Plymouth MN, USA) so as to minimize the formation of primer dimers and self-annealing of primers.
Primer extension reactions
These employed a series of 20-to 35-mer oligonucleotides homologous to segments of the 5Ј-flanking region of the MPO gene spaced by about 200 bp, since optimal analysis of primer extension experiments occurs for cDNAs less than about 200 nucleotides in length. Oligonucleotides for use in primer extension experiments (50 ng) were radiolabeled by incubation for 1 h at 37°C, together with T4 polynucleotide kinase (New England BioLabs, Beverly, MA, USA) with 4 l ␥-32 P ATP, 70 mM Tris-Cl (pH 7.6), 10 mM MgCl 2 , 5 mM dithiothreitol, in a reaction volume of 10 l. Labeling reactions were stopped by addition of 90 l TE buffer. Labeled oligonucleotides were purified using Centrisep spin columns (Princeton Separations, Adelphia, NJ, USA) and adjusted to a final volume of 100 l.
Annealing was performed by incubating 6 l oligonucleotide with 25 g RNA in buffer containing 0.3 M NaCl, 10 mM Tris-Cl (pH 7.5), 2 mM EDTA at 100°C for 5 min, after which the mixture was placed on ice for 5 min. The annealed primer/RNA was then incubated for 1 h with 200 U SuperScript RNase H-Reverse transcriptase (Gibco BRL, Rockville, MD, USA) in a total volume of 30 l of solution containing 100 mM Tris-Cl (pH 8.3), 12 mM MgCl 2 , 2 mM deoxynucleoside triphosphates, 20 mM DTT, and 1 unit/l RNasin Ribonuclease Inhibitor (Promega, San Louis Obispo, CA, USA). Primer extension was stopped by addition of 30 l stop buffer containing 10 mM Tris-Cl (pH 8.0), 500 mM NaCl, 20 mM EDTA, and 10 g tRNA. The reaction product was precipitated with 70% ethanol at −20°C for 24 h. The precipitated cDNAs were then analyzed by electrophoresis on 6% polyacrylamide gels which were exposed to X-ray film for 24-72 h at −70°C.
RT-PCR reactions
RNA preparations were treated with RNase-free DNase to remove any contaminating genomic DNA. Aliquots containing 50 g RNA were digested with 2 U RQ1 RNase-free DNase (Promega, Madison, WI, USA) in 40 mM Tris-Cl (pH 7.9), 10 mM NaCl, 6 mM MgCl 2 , 10 mM CaCl 2 . The RNA was then repurified by standard phenol/chloroform methods. RT-PCR was carried out using a Thermoscript RT-PCR System (Gibco BRL). Synthesis of cDNA was performed using random hexamers and RNA was synthesized using Thermoscript reverse transcriptase.
Northern hybridization
Preparations of total cell RNA (7 g) were run on 1.2% agarose gels containing 1 × MOPS and 6.6% formaldehyde. The gel was then capillary transferred overnight in 10 × SSC buffer to a nylon-based membrane, GeneScreen Plus (NEN, Boston, MA, USA). RNAs were fixed to the membrane by UVcrosslinking. The membrane was prehybridized in a buffer containing 50% formamide, 10% dextran sulfate, 1% SDS and 1 M NaCl for 2 h at 42°C. Probes for Northern hybridization experiments were prepared using PCR to amplify the DNA regions of interest. Primers 16 and 17 were used to generate probe for the P1 region, primers 10 and 9 were used for the P2 region, and primers 1 and 2 were used for the P3 region. Amplified PCR products were gel purified using QIAEX II (Qiagen, Valencia, CA, USA). Probes were radioactively lab-eled with alpha-32 P dCTP using a Prime-It RmT Random Primer Labeling kit (Stratagene, La Jolla, CA, USA) and purified by gel filtration through CENTRI-SEP Columns (Princeton Separations, Adelphia, NJ, USA). Labeled probe (250 ng) was denatured together with 1 mg of salmon sperm DNA and added to the prehybridized membrane. Membranes were hybridized overnight at 42°C in a hybridization oven. The membranes were then washed twice in 2 × SSC/1% SDS for 15 min at room temperature, and twice in 1 × SSC/1% SDS for 30 min at room temperature. Finally, they were washed once in 0.1 × SSC/1% SDS for 5 min at 42°C, after which they were air dried and exposed to X-ray film at −70°C. Fifteen min exposure time was used for the P1 probe, whereas 24 h exposure was required for the P2 and P3 probes because of the low levels of MPO RNA initiated at those sites. 11 Johnson et al 10 and others (reviewed in Ref.
Results
Transcription of the
3) sequenced a limited number of human MPO cDNA clones derived from uninduced HL-60 cells, and found only a single 5Ј terminus for all clones examined, suggesting that at least in these cells, only a single initiation site is used for transcription of the human MPO gene. On the other hand, our published transfection data demonstrating the existence of three separate human MPO promoters implied the existence of at least three distinct initiation sites for transcription of this gene, one corresponding to that described by Morishita and others [11] [12] [13] [14] [15] 19 and two other sites upstream from that locus. To resolve this apparent discrepancy, we carried out a series of primer extension experiments looking for MPO transcripts with initiation sites lying within a region extending from the site (bp +1) identified by previous analysis of MPO cDNA clones (corresponding to our P1 promoter) to a point 1500 bases further upstream. This region encompasses the locations of our P2 and P3 promoters, as detected by transient transfection experiments.
A series of oligonucleotide primers ranging from 16 to 28 bases in length and complementary to portions of the proximal 5Ј-flanking region of the MPO gene (at or upstream from the P1 promoter) were synthesized. The sequences of the primers were optimized so as to minimize secondary structure and dimer formation. Ten of the primers (labeled A to J), which gave informative results in primer extension studies using RNA isolated from both myeloid and non-myeloid cells, are shown in Figure 1a .
Three cell lines were used for these primer extension experiments: (1) HL-60 cells, a myeloblast cell line which is known to synthesize MPO mRNA at high levels; (2) K-562 cells, a proerythroblastic cell line which, according to previous evidence, expresses no MPO protein and little or no intact MPO mRNA; and ( approximately 118 bp in length ( Figure 3 , lane 1). This confirms the presence of an MPO RNA initiation site at the location previously described by Morishita, 19 and Hashinaka, 12 at or near bp +1 of the MPO gene (using the numbering system of Johnson et al 21 ) , and shows that this site is active in HL-60 cells. Since this initiation site also corresponds closely with the location of our previously described MPO P1 basal promoter, 17, 18 we term this the P1 initiation site. Figure 3 also demonstrates that (whereas RNA from uninduced HL-60 cells contains MPO message initiated near bp +1 of the MPO gene) RNA isolated from HL-60 cells 24 h after they have been induced to differentiate along the macrophage line of development by treatment with TPA, contains little or no MPO message initiated at this site (lane 2). This finding agrees with previous studies by ourselves 4, 13 and others 22, 23 showing that MPO mRNA synthesis is downregulated almost completely by 24 h after TPA treatment, and it shows that MPO transcription initiated at this site, presumably by the P1 promoter, is physiologically regulated. In addition, Figure 3 shows that using RNA from either untreated or TPA-treated K-562 cells (lanes 3 and 4) or equivalently treated HeLa cells (lanes 5 and 6), no detectable cDNA product is obtained using primer I. These data suggest that MPO transcription is initiated at this site by the P1 promoter only in MPO enzyme-expressing cells. Hence, initiation at this site by the P1 promoter is not only maturation stage-specific, but also tissue-specific. Primer J ( Figure 1a ) and several other primers (not shown) lying between bp −1 and bp −200 gave rise to no detectable cDNA product by primer extension using RNA from either HL-60, K-562, or HeLa cells (Figure 2a which indicated no promoter activity within this DNA segment, and argue against artifactual initiation of transcription in our system.
Using RNA from uninduced HL-60 cells, primer extension with primer E (located between bp −245 and −264) gave rise to two cDNA products 67 and 62 bp in length, respectively, as shown by the acrylamide gel illustrated in Figure 4a and Figure 2a . Comparison of these products with the molecular weight markers and the accompanying sequencing ladder, reveals two closely spaced transcription initiation sites at bp −312 and bp −307, respectively. Likewise, primer extension using primer F (located between bp −203 and bp −222) gave rise to a cDNA product 110 bp in length as demonstrated in Figure 4b and summarized in Figure 2a . This evidence implies the presence of an initiation site at bp −312, in agreement with the larger of the two bands seen with primer E. Together, these data support the existence of a second transcription start site for the MPO gene in HL-60 cells, approximately 312 bp upstream from the P1 site. While this novel initiation site appears to lie somewhat downstream from the approximate location we previously derived for our P2 promoter by a transient transfection approach, 9 that promoter was not accurately localized in our previous study. Furthermore, as shown below, no other initiation sites were observed between bp −312 and bp −900 by our primer extension experiments. Since it appears likely that the P2 promoter is responsible for initiation near bp −312, we term this the P2 initiation site.
Primer extension studies were also carried out with primer E using RNA preparations from TPA-treated HL-60 cells, as well as from untreated or TPA-treated K-562 cells or HeLa cells. Surprisingly, as shown in Figure 5 , cDNA products of the same length (arrows) were obtained using these RNAs as using RNAs from uninduced HL-60 cells. Apparent levels of cDNA product obtained with this primer were not substantially different using RNA from any of the three cell lines, nor did the intensity of the bands differ significantly as a function of TPA treatment. These findings demonstrate that MPO transcripts are initiated at this site in both MPO enzyme-expressing and MPO-non-expressing myeloid cells, and even more surprisingly, in the non-myeloid cell line HeLa. This implies that transcriptional initiation at this site shows neither maturation stage specificity nor tissue specificity. Comparable results were obtained using primer F, confirming the nonspecificity of initiation at this site (summarized in Figure 2a) .
We next examined the ability of oligonucleotides corresponding to sites upstream from the P2 initiation site to prime cDNA synthesis using RNA from HL-60 cells. Primer H, corresponding to a segment of the MPO gene from bp −369 to bp −386, and primer G, corresponding to a segment of the MPO gene from bp −473 to bp −492 (Figure 1a ) gave rise to no detectable products (Figure 2a) , suggesting the absence of initiation sites for MPO transcription in the region immediately upstream from the P2 transcription start site. Similar experiments (not shown) demonstrated no additional transcription initiation sites anywhere between bp − 300 and bp −900 of the MPO gene.
Primers A (bp −834 to −860) and B (bp −772 to −796) were designed to look for a transcription initiation site near bp −1000, to confirm our previous transfection data which had suggested the existence of a third promoter (P3) in that region. Figure 6a illustrates an acrylamide gel showing that when primer extension is carried out using RNA from uninduced HL-60 cells and primer B, a major cDNA product of about 157 bp in length and a minor cDNA product of about 150 bp in length, are produced. As summarized in Figure 2a , these data imply the existence of closely spaced initiation sites at bp −929 and bp −922, respectively. Primer extension using primer A (Figure 6b ) gave rise to a 95 bp cDNA product,
Figure 3
Polyacrylamide gel analyzing cDNA products obtained by primer extension using primer 1 with RNA preparations from HL-60, K-562 and HeLa cells, both untreated and treated for 24 h with TPA. Note that a 118 bp cDNA product is obtained using RNA from untreated HL-60 cells, but not using TPA-treated HL-60 cells or untreated or TPA-treated K-562 or HeLa cells, implying that in uninduced HL-60 cells at least some MPO mRNA is initiated at or near bp +1 of the MPO gene.
implying an initiation site identical to that obtained with primer B (summarized in Figure 2a ). This site lies in reasonable proximity to, although somewhat downstream from, the location of our previously described P3 promoter, and hence we have termed this locus 'initiation site P3'. We carried out additional primer extension experiments to look for initiation sites further upstream from the P3 site, using HL-60 cell RNA and primers C and D (as well as others not shown), but no cDNA products were obtained using any of these primers (Figure 2a) , providing additional evidence that the initiation site which we labeled 'P3' corresponds to the site of the P3 promoter activity previously defined by transient transfection experiments.
We then looked to see if MPO transcripts initiated at the P3 site could be detected in K-562 or HeLa cells. Analysis of the P3 site in these cells was of particular interest, since we had previously shown that we could obtain tissue-specific
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Figure 4
Polyacrylamide gels showing the cDNA products obtained by primer extension experiments using HL-60 RNA and primer E (a) or primer F (b). Using primer E a doublet band indicating cDNA products of approximately 67 bp and 62 bp in length is observed, implying that MPO mRNA is initiated at or near bp −312 and bp −307 of the MPO gene. Likewise, using primer F a single band corresponding to a cDNA product 110 bp in length was obtained, supporting the presence of an initiation site near bp −312.
MPO transcription in transient transfection experiments using the P3 MPO promoter, coupled with additional enhancer or inhibitor elements lying near that site. 24 As shown in Figure  7 , primer extension using RNA isolated from all three cell lines grown in the absence of TPA treatment showed initiation at the same P3 site and at comparable levels, suggesting lack of tissue specificity for transcriptional initiation at that site. Surprisingly, TPA treatment increased the apparent level of MPO mRNA initiated at this site in all cell lines, most dramatically in HeLa cells. The reason for the apparent increase in MPO transcripts in TPA-treated cells is unclear, but these results are at variance with other data suggesting that TPA treatment brings about a reduction in levels of intact MPO RNA in myeloid cell lines. Additional bands suggestive of other nonspecific sites of initiation were seen sporadically, particularly in HeLa cells, suggesting that initiation may occasionally occur at other sites as well. Overall, this evidence indicates that MPO transcriptional initiation at the P3 site shows neither Polyacrylamide gel analyzing cDNA products obtained by primer extension using primer E, with RNA preparations from HL-60, K-562 and HeLa cells, both untreated and treated for 24 h with TPA. Note that using primer E, bands corresponding to cDNA products approximately 67 and 62 bp in length (marked by arrows) are obtained using any of these RNA preparations. These results suggest that initiation of MPO RNA synthesis occurs in all of these cell types, both in the presence and in the absence of TPA treatment.
the tissue specificity nor the maturation stage specificity seen with MPO protein and enzyme activity.
MPO transcripts initiated at the upstream initiation sites (P2 and P3) do not extend into the first exon of the MPO gene, whereas transcripts initiated at the downstream initiation site (P1) extend far into the protein coding region
Previous studies of MPO enzyme activity, as well as immunohistochemical studies of MPO protein expression and Northern blotting and RT-PCR studies of human MPO mRNA levels, using primers located within coding regions of this gene, have provided substantial evidence that full length MPO mRNA and protein are synthesized only in immature myeloid cells. Data reviewed above also suggested that intact tran-
Figure 6
Polyacrylamide gels showing the cDNA products obtained by primer extension experiments using HL-60 RNA and primer B (a) or primer A (b). Using primer B, a doublet band indicating cDNA products of approximately 150 and 157 bp in length is observed, implying that MPO mRNA is initiated at or near bp −929 and bp −922. Using primer A, a single band corresponding to a cDNA product about 95 bp in length was obtained, confirming the presence of an initiation site near bp −929 of the MPO gene.
scripts of the human MPO gene may be initiated predominantly at a single site, which corresponds in location to that of our MPO P1 promoter. On the other hand, murine MPO transcripts have been shown previously to be initiated at several sites, and the primer extension experiments described in this present study demonstrated the presence in HL-60 cells of MPO mRNA molecules which had been initiated at two upstream sites in addition to the P1 site. Moreover, MPO transcripts initiated at the upstream sites (P2 and P3) were found among RNA populations of immature myeloid cell lines such as K-562, which have been shown previously by Northern blotting and RT-PCR studies not to transcribe significant amounts of intact MPO mRNA, and carcinoma lines such as HeLa which are not thought to synthesize MPO RNA or protein.
In an attempt to resolve these discrepancies, we carried out a series of RT-PCR and Northern blotting experiments, designed to verify the presence of MPO transcripts initiated upstream from the MPO P1 promoter site, and to determine if such transcripts extend into the coding region of the MPO
Figure 7
Polyacrylamide gel analyzing cDNA products obtained by primer extension using primer E with RNA preparations from HL-60, K-562 and HeLa cells, both untreated and treated for 24 h with TPA. Note that a doublet band corresponding to cDNA products approximately 150 bp and 157 bp in length is obtained using any of these RNA preparations. The intensity of the cDNA bands is greater for RNAs from TPA-treated than from untreated cells, especially in the case of HeLa cells.
gene. It should be noted that all RT-PCR experiments were carried out using DNase-treated RNA and that control reactions omitting the reverse transcriptase step were included for every set of primers. Numerous pairs of oligonucleotide primers (18-to 21-mers) suitable for amplifying different portions of the 5Ј-flanking region of the MPO gene were synthesized. Figure 1b illustrates a selection of these primers which gave informative results. A summary of those results is provided in Figure 2b .
We first carried out RT-PCR experiments to confirm that at least some of the transcripts initiated at or above the P1 transcription start site extend into the protein coding region of the MPO gene. Initially we employed primer 14, which is located slightly downstream from the P1 site, together with a series of other primers located still further downstream. For example, as shown in Figure 2b , primer pair 14 and 12 gave rise to a 265 bp product using RNA from uninduced HL-60 cells. This indicates extension of MPO RNA transcripts at least into the first exon (which lies between bp +1 and bp +334). Likewise, primer pair 14 and 13 gave rise to a 1519 bp product, indicating extension of MPO RNA molecules from the P1 site as far as the eighth exon (which lies between bp +1386 and bp +1545). Other primer pairs such as primer 16 and primer 17 showed extension of RNA molecules as far as bp +2197, into exon 11 (which lies between bp +1975 and bp +2210). Figure 8a illustrates a gel showing RT-PCR products obtained using primer pair 14 and 12 and mRNAs from HL-60 cells, K-562 cells, and HeLa cells, untreated or harvested 24 h following treatment with TPA. As this Figure shows , the expected 265 bp PCR product, including the region from bp +8 to bp +272 is seen using HL-60 cells, but not using K-562 cells or HeLa cells. This implies that HL-60 cells contain mRNA transcripts which include this portion of the MPO message, whereas these sequences are not present in RNA obtained from the other two cell lines. Using RNA isolated from HL-60 cells that have been treated for 24 h with TPA, the level of the PCR product is much less than that obtained using untreated HL-60 cells, implying a corresponding decrease in MPO mRNA levels. On the other hand, no detectable product was seen using TPA-treated K-562 cells or HeLa cells. Likewise, no product was seen using HL-60 RNA when the reverse transcriptase step was omitted, indicating that the data do not reflect DNA contaminating the RNA preparation. Figure 8b shows similar results obtained using primers 16 and 17 (spanning the region between bp +1171 and bp +2197). Again, the expected 1027 bp product was seen using RNA from HL-60 cells, but not using RNA from K-562 cells or HeLa cells. RNA from TPA-treated HL-60 cells gave rise to a lower level of product than was obtained with untreated cells, whereas TPA treatment had no effect in K-562 or HeLa cells. No product was seen using HL-60 cell RNA when the reverse Leukemia transcriptase step was omitted. Together, the data shown in Figure 8a and b demonstrate that MPO mRNA sequences extending from bp +8 to bp +2197 (including exons 1 to 11), are seen in HL-60 cell RNA but not in RNA isolated from K-562 cells or HeLa cells. Furthermore, the level of these mRNA molecules in HL-60 cells declines following TPA treatment.
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We next carried out RT-PCR experiments using primer pairs designed to examine the presence and fate of MPO mRNA transcripts initiated upstream from the P1 site. Primer pair 10 and 9 covering the region from bp −264 (slightly downstream from the P2 initiation site) to bp −26 gave rise to the expected 239 bp product in all cell lines and in both untreated and TPA-treated cells (Figure 9 and Figure 2b) . No product was obtained using HL-60 RNA when the reverse transcriptase step was omitted, indicating that the product did not arise from amplification of DNA contaminating the RNA preparation. These findings appear to support the primer extension data indicating an initiation site at P2, which lacks tissue or maturation stage specificity. However, primer pairs composed of primer 10 (located slightly downstream from the P2 site) coupled with primers 11, 12 or 13 (located within the protein coding region downstream from the P1 site) gave rise to no detectable product using RNA from any of the three cell lines, whether untreated or TPA treated (Figure 2b ). This suggests that RNA initiated at the P2 site undergoes premature termination or else is spliced to a site further downstream than primer 13. In fact, the lack of product seen in HeLa or K-562 cells using primers 16 and 17 suggests that any splice site must be further downstream than exon 11 (out of 12 exons), and hence probably beyond the coding region of the MPO gene.
RT-PCR reactions using at least one upstream primer located between bp −600 and the P2 site coupled with a more downstream primer gave rise to no detectable products ( Figure  2b ), suggesting that any mRNA molecules initiated upstream from bp −600 did not extend through this region. However, RT-PCR carried out using primer 1 (slightly downstream from the P3 initiation site) and primer 2 (150 bases downstream from that site) gave rise to a product in all three cell lines in presence or absence of TPA treatment (Figure 2b and Figure  10 ). Again, no product was seen using HL-60 RNA when the reverse transcriptase step was omitted. Interestingly, RT-PCR using primer 1 coupled with primers 3 or 4 (bp −492 to −473 and −386 to −369, respectively) gave rise to no products in any of the three cell lines tested, with or without TPA treatment (Figure 2b ). These data suggest that MPO mRNA initiated at the P3 site either undergoes premature termination or else is spliced to a more downstream site.
The locations within the 5Ј-flanking region of the MPO gene of the P1, P2, and P3 transcription initiation sites determined in the above experiments are illustrated in Figure 2c .
MPO transcripts initiated at the P2 and P3 sites in leukemic cells undergo premature termination
To attempt to determine whether MPO mRNA molecules initiated at the P2 and P3 sites are prematurely terminated or spliced to a downstream site, Northern blotting experiments were performed. MPO cDNA probes specific for sequences immediately downstream from the P3 and P2 sites, respectively, or from the protein coding region downstream from the P1 site were employed. Figure 11a illustrates a composite blot in which RNAs from untreated and TPA-treated HL-60 cells were hybridized to each of these three probes. Incubation of RNA from uninduced HL-60 cells with a 32 P-labeled exon 1
Figure 9
Agarose gel electrophoresis of RT-PCR products obtained from cDNA derived from reverse transcription of MPO mRNA preparations obtained from untreated or TPA treated HL-60, K-562 and HeLa cells using primers 9 and 10. Note that the expected 239 bp RT-PCR products are observed using RNA from either HL-60 cells, K-562 cells or HeLa cells and that RNA from TPA-treated cells gives rise to similar levels of product to those obtained using RNA from untreated cells. No product is obtained when the reverse transcriptase step is omitted.
probe (lane 1), followed by autoradiography of the blot for 15 min, revealed a major band at the size expected for MPO mRNA (open arrow). Using RNA from HL-60 cells harvested 24 h following TPA treatment, only a very faint MPO RNA band was seen under the same autoradiographic conditions (lane 2). On the other hand, incubation of RNA from either untreated or TPA-treated HL-60 cells with equivalently labeled P2 or P3 probes gave rise to no detectable bands after autoradiography for 15 min. However, autoradiography of the P2-or P3-labeled blots for 24 h revealed predominant bands (closed arrows) at about the size of yeast tRNA (about 100
Figure 10
Agarose gel electrophoresis of RT-PCR products obtained from cDNA derived from reverse transcription of MPO mRNA preparations obtained from untreated or TPA treated HL-60, K-562 and HeLa cells using primers 1 and 2. Note that the expected 150 bp RT-PCR products are observed at similar levels using RNA from any of the three cell types. Furthermore, RNA from TPA-treated cells gives rise to similar amounts of product to those obtained using untreated cells. No product is obtained when the reverse transcriptase step is omitted. bases) (lanes 3-6). These findings suggest that the amount of MPO mRNA initiated at the P2 and P3 sites in HL-60 cells is much less than that initiated at the P1 site, and that much of the MPO mRNA initiated at these sites undergoes premature termination about 100 bases downstream from its initiation site. The additional, fainter high molecular weight bands observed following autoradiography of these blots for 24 h do not correspond in size to MPO message and are most likely non-specific. Northern blots carried out using HeLa cell RNA and either P1, P2 or P3 probes gave rise to no bands after autoradiography for 15 min, confirming that little or no MPO RNA is synthesized in HeLa cells. Figure 11b illustrates two lanes of a blot obtained using the P3 probe with RNA from untreated or TPA-treated HeLa cells and subjected to autoradiography for 24 h. Allowing for minor differences in the gel from that illustrated in Figure 11a , non-specific bands similar
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Figure 11
Composite photograph of Northern blots in which electrophoresed MPO RNA from untreated and TPA-treated HL-60 cells or HeLa cells was analyzed for the presence of MPO mRNA. (a) Total RNA from untreated or TPA-treated HL-60 cells was separately analyzed using three different probes designed to differentiate transcripts initiated at P1, P2 and P3 sites in the MPO gene. Lanes 1 and 2 were hybridized to the P1 region probe, lanes 3 and 4 to the P2 probe, and lanes 5 and 6 to the P3 probe. Time of autoradiography was 15 min for the P1 probe and 24 h for the P2 and P3 probes. The open arrow indicates the typical MPO RNA band at about 3 kb observed with the P1 region probe. The closed arrows indicate the predominant low molecular weight bands (about 100 bases in size) seen with the P2 and P3 probes. (b) Total RNA from untreated or TPA-treated HeLa cells was analyzed using the P3 probe and subjected to autoradiography for 24 h. Note that relatively little RNA hybridizable to the P3 probe is detected and no band with a molecular weight corresponding to intact MPO mRNA is noted. A faint band corresponding to a molecular weight of about 100 bp is noted along with several higher molecular weight bands, thought to be non-specific.
to those seen with HL-60 RNA using the P3 probe are seen, but no specific band with the molecular weight of MPO RNA is noted. A minor band with the molecular weight about that of tRNA is noted, again suggesting possible premature termination of some transcripts. However, this band is much fainter than that obtained using HL-60 RNA. These results indicate that only minute amounts of RNA are synthesized from the P3 site in HeLa cells and that the specific band corresponding to intact MPO message is not synthesized.
Discussion
We had previously published transient transfection data which indicated the existence of three distinct promoters located within the 5Ј-flanking region of the human MPO gene. These data had suggested that differential activity of these three MPO promoters might play a role in the regulation of MPO transcription during human myeloid development. However, it was unknown whether more than one of these putative promoters was functionally important in myeloid transcription in vivo. The data described in the present paper clearly demonstrate the presence in both myeloid and non-myeloid human cell lines of MPO transcripts initiated at three distinct sites in the 5Ј-flanking region of the MPO gene, which roughly correspond in location to the sites of the three human MPO promoters which we previously described.
The initiation site located furthest downstream in the MPO gene, revealed by our primer extension data (P1), appears identical to that previously described by Morishita et al 19 and Hashinaka et al 12 in their initial descriptions of the structure of the MPO gene. In agreement with previous reports we find that MPO transcription is initiated at this site in the MPOexpressing myeloid cell line HL-60, but not in other cell lines examined (K-562 and HeLa), which have been shown to express little or no intact MPO RNA and protein. 3, 25 These observations are confirmed by our RT-PCR experiments, which indicate that transcripts initiated at the P1 promoter site in this cell line extend far into the protein coding region, at least to the eleventh exon. Furthermore, our Northern blotting experiments, such as that shown in Figure 11a , show a band consistent with intact MPO message initiated at the P1 site in HL-60 cells. In addition, both our RT-PCR and Northern blot data show downregulation of MPO mRNA initiated at the P1 site following TPA treatment, consistent with the reduction in MPO transcription following TPA treatment observed in intact cells.
On the other hand, our primer extension experiments indicate that the two putative initiation sites located further upstream (P2 at about bp −310 and P3 at about bp −925) appear to actively initiate MPO RNA synthesis in both myeloid and non-myeloid cells, albeit at a much lower rate than for the P1 site in HL-60 cells. Surprisingly, there appears to be no preferential initiation at these sites in the MPO protein-expressing cell line, HL-60, compared with the non-MPO-expressing myeloid cell line, K-562, or the squamous carcinoma cell line, HeLa. Furthermore, TPA treatment, rather than inducing a decrease in initiation of MPO mRNA at the P2 and P3 sites (as occurs at the P1 site), appears to actually increase transcription at these sites. The increase in MPO transcription at these sites following TPA treatment is discrepant with a large body of previous data suggesting that, at least in HL-60 cells, TPA treatment reduces overall MPO mRNA levels. Our RT-PCR data, together with the results of our Northern blotting experiments, suggest that at least in HL-60 cells, the explanation for this discrepancy is that most MPO mRNA molecules initiated at the P2 and P3 sites undergo premature termination. The transcripts initiated at the P2 site appear to undergo termination upstream from the P1 site, whereas those initiated at the P3 site appear to have been terminated upstream from the P2 site. A fraction of the MPO RNA initiated in HeLa cells at the P3 site appears also to undergo termination, but the remainder of the RNA which hybridizes with the P3 probe appears non-specific and may represent a totally different RNA species which just happens to contain a sequence reasonably homologous to that of the probe employed in the blotting experiment.
Our RT-PCR data, by themselves, do not exclude the possibility that these transcripts undergo alternative splicing to some downstream site. However, the absence of any MPO transcripts downstream from the P1 site demonstrable by the RT-PCR technique in K-562 or HeLa cells suggests that any splicing events must occur at a site in the mRNA more than 1500 bp downstream from the P1 site. A more definitive answer to this question is provided by our Northern blotting data, which fail to reveal even a small amount of intact MPO message initiated at the P2 or P3 sites, while demonstrating that most of the MPO mRNA synthesized at these locations, at least in HL-60 cells, is only about 100 bases in length, and hence has presumably undergone premature termination. More important, these experiments show that the level of MPO transcription initiated at the P2 and P3 sites is extremely low, compared with the number of transcripts initiated at the P1 site. Hence, it appears that P1 is by far the predominant initiation site for MPO RNA synthesis in human myeloid cells.
Previous transient transfection data obtained by Chumakov et al 20 suggested that the MPO promoter in human myeloid cells is located in the 5Ј-flanking region of the MPO gene between an Alu region situated at bp −1648 to −1345 and another Alu region situated at bp −531 to −200. Our data indicate that MPO transcripts are initiated at three distinct sites within and downstream from this region, at about bp −925, −310 and +1. We detected no evidence of transcript initiation further upstream than the P3 site.
Our finding that intact MPO transcripts in human cells are initiated essentially exclusively at the P1 site is in agreement with prior evidence obtained by other investigators from the analysis of several cDNA clones, 12, 14, 19 which suggested only a single initiation site for human MPO transcripts. For example, Chang et al, 14 on the basis of a careful analysis of four cDNA clones concluded that the size heterogeneity of MPO transcripts is due to alternative splicing of MPO message rather than to initiation of transcription at different sites. Since initiation at the P2 and P3 sites apparently seldom produces transcripts which extend into the MPO coding region, it is not surprising that the limited number of clones previously examined failed to include species initiated at these more upstream sites.
On the other hand, our finding that physiologic regulation of MPO transcription occurs almost exclusively at a single site appears to differ from previous evidence that several distinct initiation sites are employed for transcription of the murine MPO gene in mouse myeloid cells. Venturelli et al 6, 7 in sequencing several murine MPO clones, found that the clones had diverse 5Ј-ends, suggesting the presence of several separate initiation sites for MPO transcription. To test this hypothesis, Friedman et al 8 carried out Northern blotting experiments using oligonucleotide probes specific for four specific sites within and downstream from a putative untranslated exon (exon 0) located upstream from the translation start site. By these experiments, as well as confirmatory primer extension experiments, these authors obtained evidence for the existence of four distinct initiation sites in the murine MPO gene, two of which were responsible for most of the transcripts. In agreement with these observations of Venturelli et al 6, 7 and Friedman et al, 8 we recently reported 9 transient transfection data demonstrating the existence of four distinct murine MPO promoters, corresponding in location with the putative initiation sites identified by those authors. We also demonstrated the presence of three homologous promoters in the human MPO gene. 9 The importance of these diverse initiation sites in the murine MPO gene, and whether they are involved in differential regulation of MPO transcription in the mouse remain to be determined. However, the data which we provide in the present report suggest that the corresponding upstream initiation sites in the human MPO gene may play little role in physiologic regulation of MPO transcription.
The reason for the apparent premature termination of the MPO transcripts initiated at the P2 and P3 sites in human myeloid cells remains unclear. As mentioned above, the human MPO gene differs from the murine MPO gene in part by the presence of Alu sequences located in the 5Ј-flanking region of the MPO gene, one of which is located between bp −531 and bp −200. It is possible that sequences within this Alu segment are responsible for premature termination of the P3 and P2 transcripts. However, this remains a matter for speculation.
While our results do not demonstrate a significant physiologic role for the P2 and P3 promoters in MPO transcription, it remains possible that these promoters have some physiologic role we have not yet detected. It should be acknowledged that we have focused on the HL-60 cell model in the current studies and have not formally ruled out the possibility that the P2 or P3 promoters might play a more important role in MPO transcription in monocyte precursors, or perhaps at some earlier stage of myeloid differentiation. Also, we have not ruled out the possibility that these promoters might activate some other gene by RNA splicing to a downstream sequence. However, we have no evidence for this.
In summary, the present studies provide evidence for the existence of three functionally active initiation sites for MPO RNA synthesis in human cells, analogous to homologous sites active in the murine MPO gene. However, by contrast with the murine gene where physiologic transcription of intact MPO mRNA appears to originate at several distinct sites, physiologic synthesis of human MPO message appears to be initiated primarily, if not exclusively, at the P1 promoter site. Our data suggest that the few MPO transcripts initiated at the other sites mainly undergo premature termination and do not contribute substantially to synthesis of intact MPO protein.
